Marshall Wace, LLP Infinity Pharmaceuticals, Inc. Transaction History

Marshall Wace, LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.49 - $1.2 $154,911 - $379,375	-316,146 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$0.85 - $2.4 $241,479 - $681,823	-284,093 Reduced 47.33%	316,146 $359,000
Q4 2021 Feb 14, 2022	BUY	$1.86 - $3.36 $1.09 Million - $1.96 Million	584,003 Added 3596.96%	600,239 $1.35 Million
Q3 2021 Nov 15, 2021	SELL	$1.52 - $3.82 $198,369 - $498,532	-130,506 Reduced 88.94%	16,236 $56,000
Q2 2021 Aug 13, 2021	SELL	$2.66 - $3.47 $1.45 Million - $1.89 Million	-545,150 Reduced 78.79%	146,742 $438,000
Q1 2021 May 17, 2021	BUY	$1.98 - $5.36 $1.37 Million - $3.71 Million	691,892 New	691,892 $2.24 Million
Q2 2019 Aug 14, 2019	SELL	$1.43 - $1.87 $26,606 - $34,793	-18,606 Closed	0 $0
Q1 2019 May 14, 2019	SELL	$1.18 - $1.91 $28,396 - $45,964	-24,065 Reduced 56.4%	18,606 $35,000
Q4 2018 Feb 14, 2019	BUY	$1.01 - $2.78 $43,097 - $118,625	42,671 New	42,671 $50,000

1.26M

Ticker INFI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 89,277,904
Description
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of met...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.